Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:35 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 107 matching trials from the live ClinicalTrials.gov search.
Completed Phase 2 Interventional Results available

Parkinson's Disease Isradipine Safety Study

NCT00753636
Conditions
Parkinson's Disease
Interventions
Dynacirc CR (Isradipine)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Stress Response, Mental Stress, Multitasking Behavior and Multitasking Ability, Physiological Stress, Cognitive Symptoms, Motor Activity
Interventions
Cranberry juice, Placebo juice
Other
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Terminated Phase 2Phase 3 Interventional Results available

Inhaled Nitric Oxide and Neuroprotection in Premature Infants

NCT00515281
Conditions
Prematurity, Bronchopulmonary Dysplasia, Intraventricular Hemorrhage, Periventricular Leukomalacia
Interventions
inhaled nitric oxide, oxygen
Drug
Lead sponsor
University of Chicago
Other
Eligibility
2 Hours to 72 Hours
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Glioma of Brain, Craniopharyngioma, Ependymoma, Germ Cell Tumor
Interventions
Memantine, Placebo, Cognitive Assessment
Drug · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Primary Open Angle Glaucoma
Interventions
GlaucoCetin, Placebo
Dietary Supplement · Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Withdrawn Not applicable Interventional

Remote Ischemic PreConditioning (RIPC)

NCT03814850
Conditions
Unruptured Cerebral Aneurysm
Interventions
Standard Manual Aneroid Sphygmomanometer
Device
Lead sponsor
Sebastian Koch
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Miami, Florida
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Tiopronin, Placebo
Drug
Lead sponsor
E. Sander Connolly
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Gainesville, Florida • New York, New York • Seattle, Washington
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

The Role of Brain Lactate Metabolism in Neuroprotection During Healthy Aging

NCT07731451
Conditions
Aging Well, Aging
Interventions
Sodium lactate infusion, Exercise-induced hyperlactatemia
Biological · Other
Lead sponsor
Northern Arizona University
Other
Eligibility
20 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2029
U.S. locations
1
States / cities
Flagstaff, Arizona
Conditions
White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia, Periventricular White Matter Abnormalities
Interventions
Clemastine fumarate
Drug
Lead sponsor
Bridget LaMonica Ostrem, M.D., Ph.D.
Other
Eligibility
3 Weeks to 20 Weeks
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
San Francisco, California
Conditions
Extreme Prematurity
Interventions
Epo, Control
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
24 Weeks to 27 Weeks
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
19
States / cities
Little Rock, Arkansas • Gainesville, Florida • Miami, Florida + 14 more
Conditions
Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy
Interventions
Cannabidiol (CBD), oxaliplatin-based chemotherapy
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Drug Drug Interaction (DDI)
Interventions
BMS-984923, Midazolam, Caffeine, dextromethorphan
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
West Bend, Wisconsin
Conditions
Traumatic Brain Injury
Interventions
Memantine, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Conditions
Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions
Darbepoetin, Placebo
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 24 Hours
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
16
States / cities
Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more
Conditions
Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
Interventions
Levetiracetam, Keppra
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Dallas, Texas
Enrolling by invitation Phase 1Phase 2 Interventional

Topical Insulin for Glaucoma (TING2)

NCT07619482
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma
Interventions
EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month), Vehicle Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 90 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Palo Alto, California
Conditions
Multiple Sclerosis
Interventions
Avonex (Interferon beta 1a), Riluzole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
San Francisco, California
Conditions
Stroke, Acute
Interventions
Nerinetide (NA-1), 2.6 mg/kg, Placebo
Drug
Lead sponsor
NoNO Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Los Angeles, California • San Francisco, California • Torrance, California + 17 more
Conditions
Coronary Disease, Heart Diseases, Cardiovascular Diseases, Neurologic Manifestations
Interventions
Magnesium, 0.9% saline
Drug
Lead sponsor
Duke University
Other
Eligibility
55 Years and older
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 2Phase 3 Interventional Results available

Neuroprotection in Acute Ischemic Stroke

NCT03320018
Conditions
Stroke, Ischemic
Interventions
Hydrogen, Minocycline, Placebo Hydrogen, Placebo Minocycline
Drug · Other
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Stony Brook, New York
Terminated Phase 1Phase 2 Interventional Results available

Spinal Cord Injury Neuroprotection With Glyburide

NCT02524379
Conditions
Acute Spinal Cord Injury
Interventions
Glyburide
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Terminated Phase 2Phase 3 Interventional Results available

Maimonides Minocycline in Stroke Study

NCT06107725
Conditions
Stroke, Acute, Ischemic Stroke, Hemorrhagic Stroke, Mortality, Morbidity
Interventions
Minocycline
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Brooklyn, New York
Terminated Phase 3 Interventional Results available

Albumin in Acute Ischemic Stroke Trial

NCT00235495
Conditions
Ischemic Stroke
Interventions
Albumin, Saline
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 83 Years
Enrollment
841 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
69
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 48 more
Conditions
Glaucoma
Interventions
ASP2767, Sham ASP2767, Prophylactic Regimen A, Prophylactic Regimen B, Placebo for prophylactic regimen
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts